Skip to main content
Equibles
ITRMF logo

ITRMF · Iterum Therapeutics plc · Metrics

Track ITRMF — free

Use ITRMF with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ITRMF.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.03 +0.01 (+34.78%) At close · Jul 21 Q3 2025 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Nov 14, 2025

Substantial doubt about the company's ability to continue as a going concern.

“This condition raises substantial doubt about the Company's ability to continue as a going concern for one year from the date these condensed consolidated financial statements are issued.”
View the 10-Q filed Nov 14, 2025
Market Cap
$446
Shares
44.66M
Volume · Jul 21 18.8K Avg daily vol (3M) 99.9K

ITRMF metrics

51 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.03
Market cap
$446

Price action

20 metrics
Price change (1W)
-6.1%
Price change (30D)
—
Price change (3M)
+176.8%
Price change (6M)
-90.6%
Price change (YTD)
-90.7%
Price change (1Y)
-96.4%
Trailing year
Price change (5Y)
—
52-week high
$0.87
52-week low
$0.01
Change from 52-week high
-96.4%
Change from 52-week low
+297.4%
Annualized volatility
383.2%
Annualized volatility (3M)
639.7%
Beta
6.4
RSI (14D)
45.1
Price vs SMA 50
-33.1%
Price vs SMA 200
-88.4%
Avg volume (3M)
99,902
Relative volume
0.2
Average dollar volume
$4,272

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
44.66M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-6,047,756.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-14

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$20.64M
Net income (TTM)
−$26.96M
Trailing 12 months
Diluted EPS (TTM)
$-0.70
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+128.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-82.9%
Debt / equity
—
Current ratio
2.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
2.0
Interest coverage
-7.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$9.04M
Latest balance sheet
Cash & equivalents
$11.00M
Total assets
$32.50M
Total debt
$20.05M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$19.51M
Capital expenditures (TTM)
$14,000
R&D (TTM)
$4.15M
SG&A (TTM)
—
Stock compensation (TTM)
$259,000
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
2
13F filer change QoQ
-16
Institutional ownership
0.0%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-99.2%
Holder tenure
1.0
Price vs estimated holder cost
+28.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
3.9%
Latest settlement
Days to cover
—
Short-squeeze score
50 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1659323 CUSIP G6333L200 Visit website Investor relations